PD1 signal transduction pathways in T cells

Hugo Arasanz; Maria Gato-Cañas; Miren Zuazo; Maria Ibañez-Vea; Karine Breckpot; Grazyna Kochan; David Escors

doi:10.18632/oncotarget.17232

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

PD1 signal transduction pathways in T cells

Hugo Arasanz, Maria Gato-Cañas, Miren Zuazo, Maria Ibañez-Vea, Karine Breckpot, Grazyna Kochan and David Escors _

PDF | HTML | How to cite

Oncotarget. 2017; 8:51936-51945. https://doi.org/10.18632/oncotarget.17232

Metrics: PDF 7993 views | HTML 10288 views | ?

Abstract

Hugo Arasanz1,*, Maria Gato-Cañas1,*, Miren Zuazo1,*, Maria Ibañez-Vea1,*, Karine Breckpot3, Grazyna Kochan1 and David Escors1,2

1Immunomodulation Group, Navarrabiomed-Biomedical Research Centre, IdISNA, Pamplona, Spain

2Rayne Institute, Division of Infection and Immunity, University College London, London, United Kindom

3Laboratory of Molecular and Cellular Therapy Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium

*These authors have contributed equally to this work

Correspondence to:

David Escors, email: [email protected]

Grazyna Kochan, email: [email protected]

Keywords: PD-L1, PDL1, PD1, B7-H1, cancer

Received: February 28, 2017 Accepted: March 24, 2017 Published: April 19, 2017

ABSTRACT

The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high efficacies and low toxicities. Despite all the recent advances, very little is yet known on the molecular intracellular signaling pathways regulated by either PD-L1 or PD1. Here we review the current knowledge on PD1-dependent intracellular signaling pathways, and the consequences of disrupting PD1 signal transduction.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17232

Publication Alerts

Reviews:

PD1 signal transduction pathways in T cells

Abstract